- Report
- March 2024
- 197 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- March 2024
- 185 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- January 2024
- 200 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- April 2024
- 299 Pages
Global
From €5260EUR$5,450USD£4,512GBP
- Clinical Trials
- April 2024
- 220 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Newsletter
- April 2024
Global
From €1010EUR$1,121USD£897GBP
- Report
- January 2024
- 150 Pages
Global
From €4681EUR$4,850USD£4,016GBP
- Clinical Trials
- December 2023
- 2092 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- March 2024
- 184 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4778EUR$4,950USD£4,098GBP
- Report
- March 2022
- 300 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- May 2020
- 185 Pages
Global
From €4006EUR$4,150USD£3,436GBP
- Report
- January 2023
- 125 Pages
Global
From €2403EUR$2,490USD£2,062GBP
- Report
- April 2023
- 115 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- April 2023
- 117 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- July 2022
- 100 Pages
Global
From €2654EUR$2,750USD£2,277GBP
- Report
- January 2022
- 419 Pages
Global
From €9169EUR$9,500USD£7,866GBP
- Report
- January 2022
- 60 Pages
Global
From €3813EUR$3,950USD£3,270GBP
- Report
- January 2022
- 60 Pages
Global
From €3813EUR$3,950USD£3,270GBP
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more